Could Hinge Bio, Inc. unlock a new class of lupus B-cell depletion therapies?
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech’s obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Why 10x Genomics is betting on peripheral blood to decode complex immune disorders
Find out how 10x Genomics and Brigham & Women’s Hospital are using single-cell profiling to redefine autoimmune diagnostics. Can it change patient care?
AstraZeneca gains EU approval for Saphnelo self-injection pen in lupus treatment
AstraZeneca has received European Commission approval for a new subcutaneous formulation of Saphnelo (anifrolumab), allowing adult patients with systemic lupus erythematosus (SLE) to self-administer the drug via a once-weekly pre-filled pen. The regulatory decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is supported by data from the Phase […]